The wisdom of screening anybody with nares for MRSA carriage may still be questioned, but one thing is beyond doubt: there’s a lot of money to be made in the screening biz.
Cepheid, which already has a “sole source” contract with the VA healthcare system, just inked contracts with two more integrated delivery systems to start MRSA surveillance programs. With fourth quarter revenues soaring 30% (to almost 50 million dollars), Cepheid’s CEO declared MRSA to be the “key driver” for their increased sales figures. Some of this money is put to use lobbying for bills that mandate MRSA screening, some helps fund “opinion leaders”, consultants and researchers, and some helps investment portfolios grow.
By contrast, the methods Mike outlined for eradicating MRSA from his ICUs do diddly-squat to stimulate the economy.
Subscribe to:
Post Comments (Atom)
OSHA! OSHA! OSHA!
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
Back on clinical service again and having more thoughts on poor hospital design. Last month I wondered why there were no stethoscope wipe... -
Those that follow me on twitter or the blog have probably noticed my recent focus on trying to understand the emergence of compulsory influe... -
REUTERS/Athit Perawongmetha With the assistance of a great supply management team, we have been able to outfit all of our clinical staff wit...
No comments:
Post a Comment
Thanks for submitting your comment to the Controversies blog. To reduce spam, all comments will be reviewed by the blog moderator prior to publishing. However, all legitimate comments will be published, whether they agree with or oppose the content of the post.